Prevnar 13 In Older Adults Appears To Have Smooth Path To FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee to give recommendations on the Pfizer vaccine’s safety and immunogenicity using accelerated approval, but no votes mentioned.
You may also be interested in...
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
Prevnar 13 Advisory Committee Review Moved Back To November
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.